Skip to main content
PMC home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2023 Oct;27(17):1–50. doi: 10.3310/JHSW0174

Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study.

Joe Kai, Brittany Dutton, Yana Vinogradova, Nicholas Hilken, Janesh Gupta, Jane Daniels
PMCID: PMC10641716  PMID: 37924269

Abstract

BACKGROUND

Heavy menstrual bleeding is a common problem that can significantly affect women's lives until menopause. There is a lack of evidence on longer-term outcomes after seeking health care and treatment for heavy menstrual bleeding.

OBJECTIVES

To assess the continuation rates of medical treatments and the rates of ablative and surgical interventions among women who had participated in the ECLIPSE trial (ISRCTN86566246) 10 years after initial management for heavy menstrual bleeding in primary care. To explore experiences of heavy menstrual bleeding and influences on treatment for women.

DESIGN

This was a prospective observational cohort study, with a parallel qualitative study.

SETTING

Primary care.

PARTICIPANTS

A total of 206 women with heavy menstrual bleeding who had participated in the ECLIPSE trial consented to providing outcome data via a questionnaire approximately 10 years after original randomisation. Their mean age at follow-up was 54 years (standard deviation 5 years). A purposeful sample of 36 women also participated in semistructured qualitative interviews.

INTERVENTIONS

The ECLIPSE trial randomised participants to either the levonorgestrel-releasing intrauterine system (52 mg) or the usual medical treatment (oral tranexamic acid, mefenamic acid, combined oestrogen-progestogen or progesterone alone, chosen as clinically appropriate by general practitioners and women). Women could subsequently swap or cease their allocated treatment.

MAIN OUTCOME MEASURES

The main outcome measures were rates of ablative and surgical treatments; the rate of continuation of medical treatments; and quality of life using the Short Form questionnaire-36 items and EuroQol-5 Dimensions; women's experiences of heavy menstrual bleeding; and the influences on their decisions around treatment.

RESULTS

Over the 10-year follow-up period, 60 out of 206 (29%) women had received a surgical intervention [hysterectomy, n = 34 (17%); endometrial ablation, n = 26 (13%)]. Between 5 and 10 years post trial intervention, 89 women (43%) had ceased all medical treatments and 88 (43%) were using the levonorgestrel-releasing intrauterine system alone or in combination with other oral treatments. More women in the usual medical treatment group had also used the levonorgestrel-releasing intrauterine system than women in the levonorgestrel-releasing intrauterine system group. Fifty-six women (28%) used the levonorgestrel-releasing intrauterine system at 10 years. There was no statistically significant difference in generic quality-of-life scores between the two original trial groups, although small improvements in the majority of domains were seen in both groups across time. Women reported wide-ranging impacts on their quality of life and normalisation of their heavy menstrual bleeding experience as a result of the taboo around menstruation. Women's treatment decisions and experiences were influenced by the perceived quality of health-care interactions with clinicians and their climacteric status.

LIMITATIONS

Fewer than half of the original 571 participants participated; however, the cohort was clinically and demographically representative of the original trial population.

CONCLUSIONS

Medical treatments for women with heavy menstrual bleeding can be initiated in primary care, with low rates of surgical intervention and improvement in quality of life observed 10 years later. Clinicians should be aware of the considerable challenges that women with heavy menstrual bleeding experience at presentation and subsequently over time, and the importance and value to women of patient-centred communication in this context.

FUTURE WORK

Any further evaluation of treatments for heavy menstrual bleeding should include long-term evaluation of outcomes and adherence.

TRIAL REGISTRATION

The original ECLIPSE trial was registered as ISRCTN86566246.

FUNDING

This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 27, No. 17. See the NIHR Journals Library website for further project information.

Plain language summary

Heavy menstrual bleeding is a common problem that can significantly affect women’s lives, yet many women do not seek medical help. Medical treatments, such as tablets and a hormonal coil inserted in the womb, were shown to help women with heavy menstrual bleeding in a previous clinical trial that we conducted, called ECLIPSE. In the ECLIPSE trial, women provided information for 5 years after their treatment started. We planned to continue to ask these women about their periods, their symptoms and quality of life, and the treatments that they chose about 10 years after they first joined the trial. We did this using questionnaires and by interviewing women. We received questionnaires from 206 out of the 490 women (42%) who had participated in the ECLIPSE trial 10 years earlier. Responders were, on average, 54 years old, and half reported that they had reached the menopause. About 3 in 10 women overall had either received a hysterectomy or undergone destruction of the womb lining. Just over one-quarter of women were using the hormonal coil. Quality of life remained improved and was generally higher than that before treatment. There was no big difference in quality of life or in the numbers of women having surgery between those who first used tablets and those who received the coil. Women described the wide-ranging impact of heavy bleeding on their lives and the taboo around periods. Women’s experience of good or poor communication with their doctors, and thoughts about fertility and menopause, influenced the treatment choices that they made. Women’s quality of life was improved by medical treatments for heavy menstrual bleeding, even as menopause approached, and this shows the importance of these treatments. This research can help doctors and women to make more informed decisions about medical and surgical treatments.

Full text of this article can be found in Bookshelf.

References

  1. Hallberg L, Högdahl AM, Nilsson L, Rybo G. Menstrual blood loss – a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45:320–51. https://doi.org/10.3109/00016346609158455 doi: 10.3109/00016346609158455. [DOI] [PubMed]
  2. Janssen CA, Scholten PC, Heintz AP. Reconsidering menorrhagia in gynecological practice. Is a 30-year-old definition still valid? Eur J Obstet Gynecol Reprod Biol 1998;78:69–72. https://doi.org/10.1016/S0301-2115(97)00275-3 doi: 10.1016/s0301-2115(97)00275-3. [DOI] [PubMed]
  3. Shapley M, Jordan K, Croft PR. Increased vaginal bleeding: the reasons women give for consulting primary care. J Obstet Gynaecol 2003;23:48–50. https://doi.org/10.1080/0144361021000043245 doi: 10.1080/0144361021000043245. [DOI] [PubMed]
  4. Fraser IS, Mansour D, Breymann C, Hoffman C, Mezzacasa A, Petraglia F. Prevalence of heavy menstrual bleeding and experiences of affected women in a European patient survey. Int J Gynaecol Obstet 2015;128:196–200. https://doi.org/10.1016/j.ijgo.2014.09.027 doi: 10.1016/j.ijgo.2014.09.027. [DOI] [PubMed]
  5. Matteson KA, Raker CA, Clark MA, Frick KD. Abnormal uterine bleeding, health status, and usual source of medical care: analyses using the Medical Expenditures Panel Survey. J Womens Health 2013;22:959–65. https://doi.org/10.1089/jwh.2013.4288 doi: 10.1089/jwh.2013.4288. [DOI] [PMC free article] [PubMed]
  6. van den Brink MJ, Saaltink AL, Groenhof F, Kollen BJ, Berger MY, Lisman-van Leeuwen Y, Dekker JH. Incidence and treatment of heavy menstrual bleeding in general practice. Fam Pract 2017;34:673–8. https://doi.org/10.1093/fampra/cmx050 doi: 10.1093/fampra/cmx050. [DOI] [PubMed]
  7. Henry C, Ekeroma A, Filoche S. Barriers to seeking consultation for abnormal uterine bleeding: systematic review of qualitative research. BMC Womens Health 2020;20:123. https://doi.org/10.1186/s12905-020-00986-8 doi: 10.1186/s12905-020-00986-8. [DOI] [PMC free article] [PubMed]
  8. Royal College of Obstetricians and Gynaecologists. National Heavy Menstrual Bleeding Audit, Second Annual Report. 2012. URL: www.rcog.org.uk/globalassets/documents/guidelines/research–audit/nationalhmbaudit_2ndannualreport_11.07.12_forweb.pdf (accessed 9 June 2021).
  9. National Institute for Health and Care Excellence (NICE). Heavy Menstrual Bleeding: Assessment and Management. NICE Guideline [NG88]. London: NICE; 2018. URL: www.nice.org.uk/guidance/ng88 (accessed 8 April 2021). [PubMed]
  10. Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2019;9:CD000400. https://doi.org/10.1002/14651858.CD000400.pub4 doi: 10.1002/14651858.CD000400.pub4. [DOI] [PMC free article] [PubMed]
  11. Bryant-Smith AC, Lethaby A, Farquhar C, Hickey M. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2018;4:CD000249. https://doi.org/10.1002/14651858.CD000249.pub2 doi: 10.1002/14651858.CD000249.pub2. [DOI] [PMC free article] [PubMed]
  12. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2000;2:CD001016. https://doi.org/10.1002/14651858.CD000249 doi: 10.1002/14651858.CD001016. [DOI] [PubMed]
  13. Lethaby A, Wise MR, Weterings MA, Bofill Rodriguez M, Brown J. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database Syst Rev 2019;2:CD000154. https://doi.org/10.1002/14651858.CD000154.pub3 doi: 10.1002/14651858.CD000154.pub3. [DOI] [PMC free article] [PubMed]
  14. Stewart A, Cummins C, Gold L, Jordan R, Phillips W. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. BJOG 2001;108:74–86. https://doi.org/10.1111/j.1471-0528.2001.00020.x doi: 10.1111/j.1471-0528.2001.00020.x. [DOI] [PubMed]
  15. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409–20. https://doi.org/10.1056/NEJMoa1103182 doi: 10.1056/NEJMoa1103182. [DOI] [PubMed]
  16. Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421–32. https://doi.org/10.1056/NEJMoa1103180 doi: 10.1056/NEJMoa1103180. [DOI] [PubMed]
  17. Donnez J, Vázquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BC, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014;101:1565–73.e1–18. https://doi.org/10.1016/j.fertnstert.2014.02.008 doi: 10.1016/j.fertnstert.2014.02.008. [DOI] [PubMed]
  18. International Standard Randomised Controlled Trial Number (ISRCTN) Registry. Ulipristal Acetate Versus Conventional Management of Heavy Menstrual Bleeding (ISRCTN20426843). 2015. URL: www.isrctn.com/ISRCTN20426843 (accessed 27 April 2022).
  19. Medicines and Healthcare products Regulatory Agency. Ulipristal Acetate 5mg (Esmya): Further Restrictions due to Risk of Serious Liver Injury. 2021. URL: www.gov.uk/drug-safety-update/ulipristal-acetate-5mg-esmya-further-restrictions-due-to-risk-of-serious-liver-injury (accessed 9 June 2021).
  20. Middleton LJ, Champaneria R, Daniels JP, Bhattacharya S, Cooper KG, Hilken NH, et al. Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patients. BMJ 2010;341:c3929. https://doi.org/10.1136/bmj.c3929 doi: 10.1136/bmj.c3929. [DOI] [PMC free article] [PubMed]
  21. Bofill Rodriguez M, Lethaby A, Grigore M, Brown J, Hickey M, Farquhar C. Endometrial resection and ablation techniques for heavy menstrual bleeding. Cochrane Database Syst Rev 2019;1:CD001501. https://doi.org/10.1002/14651858.CD001501.pub5 doi: 10.1002/14651858.CD001501.pub5. [DOI] [PMC free article] [PubMed]
  22. Daniels JP. The long-term outcomes of endometrial ablation in the treatment of heavy menstrual bleeding. Curr Opin Obstet Gynecol 2013;25:320–6. https://doi.org/10.1097/GCO.0b013e3283630e9c doi: 10.1097/GCO.0b013e3283630e9c. [DOI] [PubMed]
  23. Bhattacharya S, Middleton LJ, Tsourapas A, Lee AJ, Champaneria R, Daniels JP, et al. Hysterectomy, endometrial ablation and Mirena® for heavy menstrual bleeding: a systematic review of clinical effectiveness and cost-effectiveness analysis. Health Technol Assess 2011;15(19). https://doi.org/10.3310/hta15190 doi: 10.3310/hta15190. [DOI] [PMC free article] [PubMed]
  24. Bansi-Matharu L, Gurol-Urganci I, Mahmood TA, Templeton A, van der Meulen JH, Cromwell DA. Rates of subsequent surgery following endometrial ablation among English women with menorrhagia: population-based cohort study. BJOG 2013;120:1500–7. https://doi.org/10.1111/1471-0528.12319 doi: 10.1111/1471-0528.12319. [DOI] [PubMed]
  25. Roberts TE, Tsourapas A, Middleton LJ, Champaneria R, Daniels JP, Cooper KG, et al. Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis. BMJ 2011;342:d2202. https://doi.org/10.1136/bmj.d2202 doi: 10.1136/bmj.d2202. [DOI] [PMC free article] [PubMed]
  26. Cooper K, Breeman S, Scott NW, Scotland G, Clark J, Hawe J, et al. Laparoscopic supracervical hysterectomy versus endometrial ablation for women with heavy menstrual bleeding (HEALTH): a parallel-group, open-label, randomised controlled trial. Lancet 2019;394:1425–36. https://doi.org/10.1016/S0140-6736(19)31790-8 doi: 10.1016/S0140-6736(19)31790-8. [DOI] [PMC free article] [PubMed]
  27. Bofill Rodriguez M, Lethaby A, Fergusson RJ. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Cochrane Database Syst Rev 2021;2:CD000329. https://doi.org/10.1002/14651858.CD000329.pub4 doi: 10.1002/14651858.CD000329.pub4. [DOI] [PMC free article] [PubMed]
  28. Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J, ECLIPSE Trial Collaborative Group. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013;368:128–37. https://doi.org/10.1056/NEJMoa1204724 doi: 10.1056/NEJMoa1204724. [DOI] [PubMed]
  29. Kai J, Middleton L, Daniels J, Pattison H, Tryposkiadis K, Gupta J, ECLIPSE trial collaborative group. Usual medical treatments or levonorgestrel-IUS for women with heavy menstrual bleeding: long-term randomised pragmatic trial in primary care. Br J Gen Pract 2016;66:e861–70. https://doi.org/10.3399/bjgp16X687577 doi: 10.3399/bjgp16X687577. [DOI] [PMC free article] [PubMed]
  30. Bancroft J. The menstrual cycle and the well being of women. Soc Sci Med 1995;41:785–91. https://doi.org/10.1016/0277-9536(95)00045-9 doi: 10.1016/0277-9536(95)00045-9. [DOI] [PubMed]
  31. Su S, Yang X, Su Q, Zhao Y. Prevalence and knowledge of heavy menstrual bleeding among gynecology outpatients by scanning a WeChat QR Code. PLOS ONE 2020;15:e0229123. https://doi.org/10.1371/journal.pone.0229123 doi: 10.1371/journal.pone.0229123. [DOI] [PMC free article] [PubMed]
  32. Matteson KA, Phipps MG, Raker CA, Cronin B, Holman L. Discussion: ‘Treatment of symptomatic uterine fibroids’ by van der Kooij et al. Am J Obstet Gynecol 2010;203:e1–6. https://doi.org/10.1016/j.ajog.2010.05.017 doi: 10.1016/j.ajog.2010.05.017. [DOI] [PubMed]
  33. Frick KD, Clark MA, Steinwachs DM, Langenberg P, Stovall D, Munro MG, Dickersin K, STOP-DUB Research Group. Financial and quality-of-life burden of dysfunctional uterine bleeding among women agreeing to obtain surgical treatment. Womens Health Issues 2009;19:70–8. https://doi.org/10.1016/j.whi.2008.07.002 doi: 10.1016/j.whi.2008.07.002. [DOI] [PubMed]
  34. Santer M, Wyke S, Warner P. What aspects of periods are most bothersome for women reporting heavy menstrual bleeding? Community survey and qualitative study. BMC Womens Health 2007;7:8. https://doi.org/10.1186/1472-6874-7-8 doi: 10.1186/1472-6874-7-8. [DOI] [PMC free article] [PubMed]
  35. Lethaby A, Farquhar C. Treatments for heavy menstrual bleeding. BMJ 2003;327:1243–4. https://doi.org/10.1136/bmj.327.7426.1243 doi: 10.1136/bmj.327.7426.1243. [DOI] [PMC free article] [PubMed]
  36. Grant C, Gallier L, Fahey T, Pearson N, Sarangi J. Management of menorrhagia in primary care – impact on referral and hysterectomy: data from the Somerset Morbidity Project. J Epidemiol Community Health 2000;54:709–13. https://doi.org/10.1136/jech.54.9.709 doi: 10.1136/jech.54.9.709. [DOI] [PMC free article] [PubMed]
  37. Santer M, Wyke S, Warner P. Women’s management of menstrual symptoms: findings from a postal survey and qualitative interviews. Soc Sci Med 2008;66:276–88. https://doi.org/10.1016/j.socscimed.2007.08.018 doi: 10.1016/j.socscimed.2007.08.018. [DOI] [PubMed]
  38. Protheroe J, Bower P, Chew-Graham C, Peters TJ, Fahey T. Effectiveness of a computerized decision aid in primary care on decision making and quality of life in menorrhagia: results of the MENTIP randomized controlled trial. Med Decis Making 2007;27:575–84. https://doi.org/10.1177/0272989X07306785 doi: 10.1177/0272989X07306785. [DOI] [PubMed]
  39. Fredericks E. Short report: How family physicians can support discussions about menstrual issues. Can Fam Physician 2014;60:e194–6. [PMC free article] [PubMed]
  40. Heliövaara-Peippo S, Hurskainen R, Teperi J, Aalto AM, Grénman S, Halmesmäki K, et al. Quality of life and costs of levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of menorrhagia: a 10-year randomized controlled trial. Am J Obstet Gynecol 2013;209:535.e1–535.e14. https://doi.org/10.1016/j.ajog.2013.08.041 doi: 10.1016/j.ajog.2013.08.041. [DOI] [PubMed]
  41. Lete I, del Carme Cuesta M, Marín JM, Martínez M, Bermejo A, Arina R. Acceptability of the levonorgestrel intrauterine system in the long-term treatment of heavy menstrual bleeding: how many women choose to use a second device? Eur J Obstet Gynecol Reprod Biol 2011;154:67–70. https://doi.org/10.1016/j.ejogrb.2010.07.040 doi: 10.1016/j.ejogrb.2010.07.040. [DOI] [PubMed]
  42. Beelen P, van den Brink MJ, Herman MC, Geomini PM, Duijnhoven RG, Bongers MY. Predictive factors for failure of the levonorgestrel releasing intrauterine system in women with heavy menstrual bleeding. BMC Womens Health 2021;21:57. https://doi.org/10.1186/s12905-021-01210-x doi: 10.1186/s12905-021-01210-x. [DOI] [PMC free article] [PubMed]
  43. Royal College of Obstetricians and Gynaecologists (RCOG). The Initial Management of Menorrhagia. Evidence-based Guideline No.1. London: RCOG; 1998.
  44. Thirlaway K, Fallowfield L, Cuzick J. The Sexual Activity Questionnaire: a measure of women’s sexual functioning. Qual Life Res 1996;5:81–90. https://doi.org/10.1007/BF00435972 doi: 10.1007/BF00435972. [DOI] [PubMed]
  45. Shaw RW, Brickley MR, Evans L, Edwards MJ. Perceptions of women on the impact of menorrhagia on their health using multi-attribute utility assessment. Br J Obstet Gynaecol 1998;105:1155–9. https://doi.org/10.1111/j.1471-0528.1998.tb09968.x doi: 10.1111/j.1471-0528.1998.tb09968.x. [DOI] [PubMed]
  46. Pattison H, Daniels JP, Kai J, Gupta JK. The measurement properties of the menorrhagia multi-attribute quality-of-life scale: a psychometric analysis. BJOG 2011;118:1528–31. https://doi.org/10.1111/j.1471-0528.2011.03057.x doi: 10.1111/j.1471-0528.2011.03057.x. [DOI] [PubMed]
  47. Matteson KA, Boardman LA, Munro MG, Clark MA. Abnormal uterine bleeding: a review of patient-based outcome measures. Fertil Steril 2009;92:205–16. https://doi.org/10.1016/j.fertnstert.2008.04.023 doi: 10.1016/j.fertnstert.2008.04.023. [DOI] [PMC free article] [PubMed]
  48. Gibbons E, Mckintosh A, Fitzpatrick R. A Structured Review of Patient-reported Outcome Measures for People Undergoing Elective Procedures for Benign Gynaecological Conditions of the Uterus: Report to the Department of Health. Oxford: University of Oxford; 2010.
  49. Habiba M, Julian S, Taub N, Clark M, Rashid A, Baker R, Szczepura A. Limited role of multi-attribute utility scale and SF-36 in predicting management outcome of heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol 2010;148:81–5. https://doi.org/10.1016/j.ejogrb.2009.09.021 doi: 10.1016/j.ejogrb.2009.09.021. [DOI] [PubMed]
  50. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2008;1:CD001016. https://doi.org/10.1002/14651858.CD001016.pub2 doi: 10.1002/14651858.CD001016.pub2. [DOI] [PubMed]
  51. Ware J, Kosinski M, Gandek B. SF-36 Health Survey: Manual & Interpretation Guide. Lincoln, RI: QualityMetric Incorporated; 1993.
  52. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77–101. https://doi.org/10.1191/1478088706qp063oa
  53. Creswell JW. Qualitative Inquiry and Research Design: Choosing Among Five Approaches. 2nd edn. Thousand Oaks, CA: SAGE Publications, Inc.; 2007. pp. 202–3.
  54. Aalto AM, Aro A, Teperi J. RAND-36 as a Measure of Health-related Quality of Life: Reliability, Construct Validity and Reference Values in the Finnish General Population. Helsinki: STAKES, Research Reports 101; 1999.
  55. Meaidi A, Kuhr Skals R, Alexander Gerds T, Lidegaard O, Torp-Pedersen C. Decline in Danish use of oral tranexamic acid with increasing use of the levonorgestrel-releasing intrauterine system: a nationwide drug utilization study. Contraception 2020;101:321–6. https://doi.org/10.1016/j.contraception.2019.12.013 doi: 10.1016/j.contraception.2019.12.013. [DOI] [PubMed]
  56. O’Flynn N, Britten N. Menorrhagia in general practice – disease or illness. Soc Sci Med 2000;50:651–61. https://doi.org/10.1016/S0277-9536(99)00318-4 doi: 10.1016/s0277-9536(99)00318-4. [DOI] [PubMed]
  57. O’Flynn N, Britten N. Diagnosing menstrual disorders: a qualitative study of the approach of primary care professionals. Br J Gen Pract 2004;54:353–8. [PMC free article] [PubMed]
  58. Garside R, Britten N, Stein K. The experience of heavy menstrual bleeding: a systematic review and meta-ethnography of qualitative studies. J Adv Nurs 2008;63:550–62. https://doi.org/10.1111/j.1365-2648.2008.04750.x doi: 10.1111/j.1365-2648.2008.04750.x. [DOI] [PubMed]
  59. O’Flynn N. Menstrual symptoms: the importance of social factors in women’s experiences. Br J Gen Pract 2006;56:950–7. [PMC free article] [PubMed]
  60. Santer M. Heavy menstrual bleeding: delivering patient-centred care. Br J Gen Pract 2008;58:151–2. https://doi.org/10.3399/bjgp08X277258 doi: 10.3399/bjgp08X277258. [DOI] [PMC free article] [PubMed]
  61. Byles JE, Hanrahan PF, Schofield MJ. ‘It would be good to know you’re not alone’: the health care needs of women with menstrual symptoms. Fam Pract 1997;14:249–54. https://doi.org/10.1093/fampra/14.3.249 doi: 10.1093/fampra/14.3.249. [DOI] [PubMed]
  62. Chapple A. Menorrhagia: women’s perceptions of this condition and its treatment. J Adv Nurs 1999;29:1500–6. https://doi.org/10.1046/j.1365-2648.1999.01038.x doi: 10.1046/j.1365-2648.1999.01038.x. [DOI] [PubMed]
  63. Paramsothy P, Harlow SD, Greendale GA, Gold EB, Crawford SL, Elliott MR, et al. Bleeding patterns during the menopausal transition in the multi-ethnic Study of Women’s Health Across the Nation (SWAN): a prospective cohort study. BJOG 2014;121:1564–73. https://doi.org/10.1111/1471-0528.12768 doi: 10.1111/1471-0528.12768. [DOI] [PMC free article] [PubMed]
  64. Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 2011;113:3–13. https://doi.org/10.1016/j.ijgo.2010.11.011 doi: 10.1016/j.ijgo.2010.11.011. [DOI] [PubMed]
  65. Warner P, Whitaker LHR, Parker RA, Weir CJ, Douglas A, Hansen CH, et al. Low dose dexamethasone as treatment for women with heavy menstrual bleeding: a response-adaptive randomised placebo-controlled dose-finding parallel group trial (DexFEM). EBioMedicine 2021;69:103434. https://doi.org/10.1016/j.ebiom.2021.103434 doi: 10.1016/j.ebiom.2021.103434. [DOI] [PMC free article] [PubMed]

RESOURCES